Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

NICE rejects breast cancer drugs

  • Comment

Two drugs have been rejected for use on the NHS to treat breast cancer when combined with other therapies following a consultation.

NICE turned down an application to use Tyverb (lapatinib) and Herceptin (trastuzumab) in combination with an aromatase inhibitor, another type of breast cancer treatment.

The draft guidance, which is open to consultation, does not recommend using the drugs in this way for treating advanced breast cancer that is both hormone-receptor and HER2-positive.

Tyverb would cost around £28,000 per patient for a year of treatment in this setting, while Herceptin - which is approved on the NHS for other breast cancers - would cost about £26,000.

NICE chief executive Sir Andrew Dillon said the data relating to whether patients lived longer with the drugs was uncertain.

Almost 46,000 women in the UK are diagnosed with breast cancer every year, and up to 80% have hormone receptor-positive breast cancer, which means that cancer cells depend on female hormones, including oestrogen, to grow.

These tumours can also sometimes be HER2-positive, which means that cells grow and divide quicker and the cancer is more aggressive.

NICE also published final advice to the NHS on the use of Avastin (bevacizumab) for bowel cancer that has spread to other organs, confirming previous pieces of guidance rejecting the drug.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs